Jafry NH, Sarwar S, Waqar T, Mubarak M. Clinical course and outcome of adult patients with primary focal segmental glomerulosclerosis with kidney function loss on presentation. World J Nephrol 2024; 13(4): 98932 [DOI: 10.5527/wjn.v13.i4.98932]
Corresponding Author of This Article
Muhammed Mubarak, MD, Full Professor, Department of Histopathology, Sindh Institute of Urology and Transplantation, Chand Bibi Road, Karachi 74200, Sindh, Pakistan. drmubaraksiut@yahoo.com
Research Domain of This Article
Urology & Nephrology
Article-Type of This Article
Observational Study
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Nephrol. Dec 25, 2024; 13(4): 98932 Published online Dec 25, 2024. doi: 10.5527/wjn.v13.i4.98932
Table 1 Demographic characteristics, clinical features, biochemical and histopathological results of adult patients of focal segmental glomerulosclerosis with kidney function loss at presentation, n = 98
Parameters
Results
Age in years
30.9 ± 13.6
Sex as male:female
2.5:1
Systolic BP in mmHg
132.7 ± 19.8
Diastolic BP in mmHg
87.4 ± 12.7
Initial proteinuria in mg/24 hours
5945.1 ± 4007.9
Serum albumin in g/dL
2.1 ± 1.0
Serum creatinine in mg/dL
2.2 ± 1.3
Renal insufficiency in males
70 (71.4)
Renal insufficiency in females
28 (28.6)
Estimated glomerular filtration rate on presentation in mL/minute/1.73 m2
37.1 ± 12.8
Histopathological findings
Number of glomeruli
16.4 ± 8.2
Number of glomeruli with global sclerosis
3.4 ± 2.9
Number of glomeruli with segmental sclerosis
3.1 ± 3.0
Tubular atrophy
Mild
41 (41.8)
Moderate
11 (11.2)
Fibrointimal thickening of arteries
Mild
9 (4.2)
Moderate
4 (4.1)
Focal segmental glomerulosclerosis variants
Not otherwise specified
43 (43.9)
Tip
20 (20.4)
Collapsing
19 (19.4)
Hilar
1 (1.0)
Cellular
1 (1.0)
Unknown/unclassified
14 (14.3)
Table 2 Treatment responses and follow-up information of adult patients with primary focal segmental glomerulosclerosis with kidney function loss at presentation who received steroid treatment, n = 81
Parameters
Results
Follow-up duration in weeks
136.8 ± 20.6
Total steroid dose in mg
4391.5 ± 1502.4
Duration of steroid treatment in weeks
19.9 ± 14.4
Time to remission in weeks
11.3 ± 6.7
Complete remission
20/81 (24.6)
Partial remission
9/81 (11.1)
No remission
52/81 (64.1)
Spontaneous remission
2 (2.4)
Table 3 Comparison of main demographic, clinical, and laboratory parameters among steroid-responsive and non-responsive adult patients with primary focal segmental glomerulosclerosis with kidney function loss at presentation and treated with steroids, n = 81
Parameters
Steroid-responsive group, n = 29
Steroid non-responsive group, n = 52
P value
Age in years
32.9 ± 13.3
38.2 ± 15.2
0.123
Sex as male:female
3.8:1
2.1:1
0.251
Systolic BP in mmHg
132.1 ± 22.2
131.8 ± 18.6
0.946
Diastolic BP in mmHg
84.9 ± 13.2
87.5 ± 12.7
0.380
Initial protein in mg/24 hours
5161.9 ± 3615.2
5803.1 ± 3879.4
0.569
Serum albumin in g/dL
1.87 ± 1.06
2.05 ± 1.01
0.492
Serum creatinine in mg/dL
2.105 ± 1.81
2.20 ± 0.92
0.748
Estimated glomerular filtration rate on presentation in mL/minute/1.73 m2
43.2 ± 11.8
35.5 ± 11.2
0.006
Cumulative steroid dose in mg/kg
34.5 ± 32.1
48.4 ± 37.8
0.097
Duration of steroid use in weeks
22.8 ± 21.7
18.3 ± 7.9
0.180
Histopathological findings
Number of glomeruli
17.25 ± 6.78
16.67 ± 9.32
0.806
Number of glomeruli with global sclerosis
2.55 ± 1.64
3.63 ± 3.89
0.396
Number of glomeruli with segmental sclerosis
2.53 ± 1.64
4.37 ± 3.56
0.057
Tubular atrophy
Mild
5 (100)
4 (66.7)
0.455
Moderate
0 (0)
2 (33.3)
Fibrointimal thickening of arteries
Mild
22 (91.7)
17 (68)
0.074
Moderate
2 (8.3)
8 (32)
Focal segmental glomerulosclerosis variants
Not otherwise specified
15 (51.7)
24 (46.2)
0.012
Tip
11 (37.9)
7 (13.5)
Collapsing
2 (6.9)
15 (28.8)
Hilar
1 (3.4)
0 (0)
Cellular
0 (0)
1 (1.9)
Unknown/unclassified
0 (0)
5 (9.6)
Table 4 Comparison of main clinicopathological parameters and outcomes among the two groups [those with kidney function loss (n = 81) and those with normal kidney function (n = 254) at presentation] of adult focal segmental glomerulosclerosis patients treated with steroids
Parameters
Kidney function loss, n = 81
Normal kidney function, n = 254
P value
Age in years
36.3 ± 14.7
26.5 ± 10.4
< 0.001
Sex as male:female
2.5:1
1.9:1
0.328
Systolic in mmHg
131.9 ± 19.8
128.4 ± 17.9
1.464
Diastolic in mmHg
86.5 ± 12.8
83.9 ± 12.2
1.664
Serum albumin in g/dL
1.9 ± 1.0
1.9 ± 1.1
0.807
Initial proteinuria in mg/24 hours
5626.2 ± 3787
4396.0 ± 2805.2
0.009
Serum creatinine in mg/dL
2.2 ± 1.3
0.8 ± 0.2
< 0.001
Follow-up duration in weeks
136.8 ± 120.6
152.94 ± 115.6
0.243
Total steroid dose in mg
4391.5 ± 1502.3
4279.6 ± 2039.5
0.649
Duration of steroid treatment in weeks
19.90 ± 14.4
23.27 ± 23.9
0.231
Time to remission
11.3 ± 6.7
12.6 ± 20.4
0.705
Number of glomeruli with global sclerosis
3.6 ± 2.9
2.0 ± 1.5
< 0.001
Number of glomeruli with segmental sclerosis
3.2 ± 3.2
2.9 ± 2.6
0.61
Tubular atrophy
Mild
39 (79.6)
133 (90.5)
0.044
Moderate
10 (20.4)
14 (9.5)
Outcomes
Complete remission
20/81 (24.7)
66/254 (25.9)
0.428
Partial remission
9/81 (11.1)
42/254 (16.5)
No remission
52/81 (64.2)
146/254 (57.4)
Doubling of serum creatinine
13/52 (25.0)
16/146 (10.9)
0.007
Citation: Jafry NH, Sarwar S, Waqar T, Mubarak M. Clinical course and outcome of adult patients with primary focal segmental glomerulosclerosis with kidney function loss on presentation. World J Nephrol 2024; 13(4): 98932